Depression with physical symptoms: Treating to remission

Journal of Clinical Psychiatry

Volumn 64, Issue SUPPL. 7, 2003, Pages 24-28

  Fava, Maurizio ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; DULOXETINE; MILNACIPRAN; MIRTAZAPINE; NORADRENALIN UPTAKE INHIBITOR; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; VENLAFAXINE;

ALGORITHM; CLINICAL TRIAL; DEPRESSION; DISEASE COURSE; DISEASE SEVERITY; DRUG CHOICE; DRUG EFFICACY; HAMILTON SCALE; HUMAN; PATIENT COMPLIANCE; PHYSICAL DISEASE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; QUESTIONNAIRE; REMISSION; REVIEW; SIDE EFFECT;

ANTIDEPRESSIVE AGENTS; COMORBIDITY; DECISION TREES; DEPRESSIVE DISORDER; DRUG ADMINISTRATION SCHEDULE; HUMANS; PAIN; PSYCHIATRIC STATUS RATING SCALES; TREATMENT OUTCOME;

EID: 0038242110     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994
2. Fava M. Somatic symptoms, depression, and antidepressant treatment [commentary]. J Clin Psychiatry 2002;63:305-307
3. Den Boer JA, Evans DL, Lee S, et al. Unraveling the diagnostic clues of depression and GAD: the primary care challenge. Psychopharmacol Bull 2002;35(suppl 2):150-157
4. Stahl SM. Does depression hurt? [BRAINSTORMS] J Clin Psychiatry 2002; 63:273-274
5. Bridges KW, Goldberg DP. Somatic presentation of DSM-III psychiatric disorders in primary care. J Psychosom Res 1985;29:563-569
6. Allgulander C, Kasper S. Coping with somatic comorbidities: striving for complete recovery. Psychopharmacol Bull 2000;36(suppl 2):103-111
7. Kellner R. A symptom questionnaire. J Clin Psychiatry 1987;48:268-274
8. Fava M, Dunner DL, Greist JH, et al. Efficacy and safety of mirtazapine in major depressive disorder patients after SSRI treatment failure: an open-label trial. J Clin Psychiatry 2001;62:413-420
9. Derogatis LR, Lipman RS, Rickels K, et al. The Hopkins Symptom Checklist (HSCL): a self-report symptom inventory. Behav Sci 1974;19: 1-15
10. Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-389
11. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967;6:278-296
12. Zung WWK. The role of rating scales in drug trials in depressive disorders. In: Fava M, Rosenbaum JF, eds. Research Designs and Methods in Psychiatry. New York, NY: Elsevier Science; 1992:277-296
13. Tedlow JR, Fava M, Uebelacker L, et al. Outcome definitions and predictors in depression. Psychother Psychosom 1998;676:266-270
14. Frank E, Prien RF, Jarrett RB, et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Arch Gen Psychiatry 1991;48:851-855
15. Hirschfeld RMA, Montgomery SA, Aguglia E, et al. Partial response and nonresponse to antidepressant therapy: current approaches and treatment options. J Clin Psychiatry 2002;63:826-837
16. Denninger JW, Mahal Y, Merens W, et al. The relationship between somatic symptoms and depression. In: New Research Abstracts of the 155th annual meeting of the American Psychiatric Association; May 21, 2002; Philadelphia, Pa. Abstract NR251:68-69
17. Keller MB. Long-term treatment strategies in affective disorders. Psychopharmacol Bull 2002;36(suppl 2):36-48
18. Keller MB, Berndt ER. Depression treatment: a lifelong commitment? Psychopharmacol Bull 2002;36(suppl 2):133-141
19. Segal Z, Vincent P, Levitt A. Efficacy of combined, sequential and crossover psychotherapy and pharmacotherapy in improving outcomes in depression. J Psychiatry Neurosci 2002;27:281-290
20. Paykel ES, Ramana R, Cooper Z, et al. Residual symptoms after partial remission: an important outcome in depression. Psychol Med 1995;25: 1171-1180
21. Ramana R, Paykel ES, Cooper Z, et al. Remission and relapse in major depression: a two-year prospective follow-up study. Psychol Med 1995;25: 1161-1170
22. Paykel ES. Achieving gains beyond response. Acta Psychiatr Scand Suppl 2002;415:12-17
23. Judd LL, Paulus MJ, Schettler PJ, et al. Does incomplete recovery from first lifetime major depressive episode herald a chronic course of illness? Am J Psychiatry 2000;157:1501-1504
24. Thase ME, Trivedi M. Optimizing treatment outcomes for patients with depression and generalized anxiety disorder. Psychopharmacol Bull 2002; 36(suppl 2):93-102
25. Zajecka JM, Jeffries H, Fawcett J. The efficacy of fluoxetine combined with a heterocyclic antidepressant in treatment-resistant depression: a retrospective analysis. J Clin Psychiatry 1995;56:338-343
26. Worthington J, Fava M, Davidson K, et al. Patterns of improvement in depressive symptoms with fluoxetine treatment. Psychopharmacol Bull 1995;31:223-226
27. Fava M, Rush AJ, Trivedi MH, et al, for the STAR*D Investigators Group. Background and rationale for the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study. Psychiatr Clin North Am 2003;26: 1-18
28. Sequenced Treatment and Alternatives to Relieve Depression: A Study Funded by the National Institute of Mental Health. About treatment options. Available at: http://www.edc.gsph.pitt.edu/stard/public/about2.html. Accessed Dec 30, 2002
29. Quitkin FM, McGrath PJ, Stewart JW, et al. Chronological milestones to guide drug change: when should clinicians switch antidepressants? Arch Gen Psychiatry 1996;53:785-792
30. Nierenberg AA, McLean NE, Alpert JE, et al. Early nonresponse to fluoxetine as a predictor of poor 8-week outcome. Am J Psychiatry 1995; 152:1500-1503
31. Danish University Antidepressant Group. Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. J Affect Disord 1990;18:289-299
32. Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 2001;178:234-241
33. Ansari A. The efficacy of newer antidepressants in the treatment of chronic pain: a review of current literature. Harv Rev Psychiatry 2000;7:257-277
34. Collins SL, Moore RA, McQuay HJ, et al. Antidepressants and anticonvulsants for diabetic neuropathy and postherapeutic neuralgia: a quantitative systematic review. J Pain Symptom Manage 2000;20:449-458
35. Lynch M. Antidepressants as analgesics: a review of randomized controlled trials. J Psychiatry Neurosci 2001;26:30-36
36. Sindrup SH, Jensen TS. Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain 1999;83:389-400
37. Barkin RL, Fawcett J. The management challenges of chronic pain: the role of antidepressants. Am J Ther 2000;7:31-47
38. Jones SL. Descending noradrenergic influences on pain. Prog Brain Res 1991;88:381-394
39. Richardson BP. Serotonin and nociception. Ann N Y Acad Sci 1990;600: 511-519
40. Willis WD, Westlund KN. Neuroanatomy of the pain system and the pathways that modulate pain. J Clin Neurophysiol 1997;14:2-31
41. Artigas F, Nutt DJ, Shelton R. Mechanism of action of antidepressants. Psychopharmacol Bull 2002;36(suppl 2):123-132
42. Anttila SA, Leinonen EV. A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev 2001;7:249-264
43. Karpa KD, Cavanaugh JE, Lakoski JM. Duloxetine pharmacology: profile of a dual monoamine modulator. CNS Drug Rev 2002;8:361-376
44. Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG, et al. Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes and other neuronal receptors. Neuropsychopharmacology 2001;26:870-880
45. Detke MJ, Lu Y, Goldstein DJ, et al. Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression. J Psychiatr Res 2002;36:383-390
46. Stahl SM, Nierenberg AA, Gorman JM. Evidence of early onset of antidepressant effect in randomized controlled trials. J Clin Psychiatry 2001;62:17-23
47. Wong DT, Bymaster FP. Dual serotonin and noradrenaline uptake inhibitor class of antidepressants potential for greater efficacy or just hype? Prog Drug Res 2002;58:169-222
48. Goldstein DJ, et al. Duloxetine in the treatment of depression: a double-blind controlled comparison with paroxetine. Br J Psychiatry. In press
49. Fava M, Wohlreich M, Mallinckrodt CH, et al. Alleviation of painful physical symptoms associated with depression: associated with higher remission rates? Presented at the 41 st annual meeting of the American College of Neuropsychopharmacology; Dec 8-12, 2002; San Juan, Puerto Rico
50. Raine R, Haines A, Sensky T, et al. Systematic review of mental health interventions for patients with common somatic symptoms: can research evidence from secondary care be extrapolated to primary care? BMJ 2002; 325:1082-1093